<DOC>
	<DOCNO>NCT00557791</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness three dos intravitreal bevasiranib sodium maintenance therapy Age-Related Macular Degeneration follow initiation anti-VEGF therapy three dos Lucentis速 .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Evaluating Combination Bevasiranib &amp; Lucentis Therapy Wet AMD ( CARBON )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients must age 50 year old Patients must predominantly classic , minimally classic occult classic lesion secondary Age Related Macular Degeneration . The study eye must ETDRS best correct visual acuity 69 24 letter ( 20/40 20/320 Snellen equivalent ) . Patients must willing able return schedule monthly followup visit twoyears . Prior pharmacologic treatment AMD study ( patient previously receive Avastin速/Lucentis速 , Macugen速 , antiVEGF agent , steroid treatment , PDT , radiation treatment , experimental therapy AMD study eye ) Any intraocular surgery study eye within 12 week screen Previous posterior vitrectomy study eye Advanced glaucoma intraocular pressure 22 mm Hg study eye despite treatment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AMD</keyword>
	<keyword>ARMD</keyword>
	<keyword>Exudative Macular Degeneration</keyword>
	<keyword>Bevasiranib</keyword>
	<keyword>siRNA</keyword>
</DOC>